Ornament2.png

Clofion

Clofion is indicated for the prevention of atherothrombotic events in : 

  • Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 

  • Patients suffering from acute coronary syndrome : 

  • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction). In combination with Acetylsalicylic acid (ASA).

  • ST segment elevation acute myocardial infarction. In combination with ASA in medically treated patients eligible for thrombolytic therapy.

Short Description

Clofion containing Clopidogrel bisulfate (equivalent to Clopidogrel) is available in 75 mg film coated tablet.

Indications

Clofion is indicated for the prevention of atherothrombotic events in : 

  • Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. 

  • Patients suffering from acute coronary syndrome : 

  • Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction). In combination with Acetylsalicylic acid (ASA).

  • ST segment elevation acute myocardial infarction. In combination with ASA in medically treated patients eligible for thrombolytic therapy.

Specification

Composition :

Each Clofion Film coated tablet 75 mg contains Clopidogrel bisulfate equivalent to Clopidogrel 75 mg


Clofion Film coated tablet 75 mg 

Box, 3 strips @ 10 film coated tablets

multi-gyn.png

Cardiovascular & Hematopoietic Systems Product